Table 2 Association of genetic variants of autophagy core genes with primary resistance or acquired resistance of gefitinib.

From: Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib

Genes

SNPs

Genotypes

Patients No. (%)

Primary resistance

Acquired resistance

HR (95% CI)

P

HR (95% CI)

P

ATG5

rs510432

GG

105

Reference

 

Reference

 

43(40.95)

GA

41(39.05)

0.54 (0.25-1.15)

0.107

0.95 (0.55-1.62)

0.838

AA

21(20.00)

0.34 (0.13-0.93)

0.035

1.28 (0.67-2.46)

0.453

GA + AA

62(59.05)

0.45 (0.24-0.87)

0.017

1.05 (0.65-1.69)

0.848

ATG5

rs688810

TT

106

Reference

 

Reference

 

41(38.68)

TC

43(40.57)

1.67 (0.77-3.63)

0.194

0.99 (0.52-1.89)

0.972

CC

22(20.75)

1.76 (0.74-4.20)

0.200

0.96 (0.42-2.17)

0.912

TC + CC

65(61.32)

1.70 (0.85-3.41)

0.132

1.03 (0.57-1.85)

0.920

ATG10

rs10036653

AA

107

Reference

 

Reference

 

40(37.38)

AT

52(48.60)

0.74 (0.35-1.54)

0.418

0.61(0.32-1.18)

0.142

TT

15(14.02)

0.66 (0.23-1.86)

0.432

0.39 (0.13-1.20)

0.101

AT + TT

67(62.62)

0.77 (0.40-1.50)

0.446

0.59 (0.32-1.10)

0.099

ATG10

rs1864182

TT

113

Reference

 

Reference

 

96(84.96)

TG

16(14.16)

2.07 (0.91-4.72)

0.082

0.30 (0.09-0.97)

0.044

GG

1(0.88)

N.C.

N.C.

N.C.

N.C.

TG + GG

17(15.04)

2.27 (1.04-4.97)

0.040

0.30 (0.09-0.97)

0.044

Genes

SNPs

Genotypes

Patients with EGFR mutation No. (%)

Primary resistance of patients with EGFR mutations

Acquired resistance of patients with EGFR mutations

HR (95% CI)

P

HR (95% CI)

P

ATG5

rs510432

GG

78

Reference

 

Reference

 

33(42.31)

GA

28(35.90)

0.56 (0.22-1.41)

0.217

0.65 (0.26-1.62)

0.353

AA

17(21.79)

0.24 (0.07-0.85)

0.026

0.77 (0.29-2.05)

0.605

GA + AA

45(57.69)

0.39 (0.18-0.85)

0.018

0.74 (0.34-1.60)

0.448

ATG5

rs688810

TT

80

Reference

 

Reference

 

31(38.75)

TC

31(38.75)

2.89 (1.05-8.01)

0.041

0.94 (0.45-1.99)

0.877

CC

18(22.50)

3.02 (1.11-8.19)

0.030

1.21 (0.46-3.23)

0.700

TC + CC

49(61.25)

3.01 (1.26-7.22)

0.014

1.07 (0.54-2.10)

0.854

ATG10

rs10036653

AA

80

Reference

 

Reference

 

28(35.00)

AT

43(53.75)

0.66 (0.29-1.53)

0.332

0.41 (0.21-0.83)

0.013

TT

9(11.25)

0.60 (0.17-2.12)

0.423

0.29 (0.06-1.38)

0.120

AT + TT

52(65.00)

0.66 (0.31-1.40)

0.278

0.37 (0.19-0.72)

0.004

ATG10

rs1864182

TT

81

Reference

 

Reference

 

70(86.42)

TG

10(12.35)

1.75 (0.63-4.87)

0.283

0.55 (0.17-1.81)

0.323

GG

1(1.23)

N.C.

N.C.

N.C.

N.C.

TG + GG

11(13.58)

2.00 (0.78-5.15)

0.149

0.55 (0.17-1.81)

0.323

  1. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between SNPs and geifitinib-resistance were estimated by Cox regression adjusted by sex, age, smoking status, ECGO and stages. N.C., not calculated.
Back to article page